研究文章
单一的低密度脂蛋白Apheresis不改善长期Hypercholesterolemic治疗患者的血管内皮功能
表3
等离子体抗氧化剂,氧化的标志/ nitrative压力,之前和一氧化氮状况的病人后(前)和低密度脂蛋白apheresis治疗。
|
|
精准医疗 |
帖子 |
1 d |
3 d |
7 d |
14 d |
(时间) |
|
| α生育酚,µ摩尔/升 |
63.68±46.85 |
21.88±12.24 |
36.92±20.58 |
44.50±23.30__ |
50.60±27.36__ |
53.77±29.11__ |
< 0.01 |
| Δα生育酚,% |
- - - - - - |
−63.0±5.1 |
−36.4±14.0 |
−23.2±14.0__ |
−13.2±15.2__ |
−8.6±12.4__ |
< 0.01 |
| γ生育酚,µ摩尔/升 |
3.89±2.55 |
1.72±1.11 |
3.52±2.87 |
3.75±2.21 |
4.60±2.37__ |
4.76±2.48 |
< 0.01 |
| Δγ生育酚,% |
- - - - - - |
−52.2±14.8 |
−14.4±21.2 |
0.4±12.3__ |
34.0±51.9__ |
25.0±33.3 |
< 0.01 |
| 硝基γ生育酚,nmol / L |
128.52±53.79 |
39.84±17.91 |
69.44±43.47 |
80.39±48.81 |
96.27±43.29__ |
104.76±41.45__ |
< 0.01 |
| Δnitro -γ生育酚,% |
- - - - - - |
−69.2±1.9 |
−49.0±13.6 |
−40.8±14.8 |
−25.0±13.0__ |
−16.4±19.4__ |
< 0.01 |
| MDA,µ摩尔/升 |
1.00±0.12 |
1.10±0.17 |
0.94±0.17 |
0.94±0.13 |
1.04±0.10 |
1.13±0.20 |
0.17 |
| ΔMDA, % |
- - - - - - |
10.6±15.9 |
−6.2±10.9 |
−6.0±15.8 |
4.6±15.6 |
14.0±26.1 |
0.18 |
| ADMA, nmol / L |
607.9±171.4 |
610.9±61.6 |
624.5±51.7 |
624.2±88.9 |
656.0±116.6 |
571.8±102.8 |
0.52 |
| ΔADMA, % |
- - - - - - |
4.2±17.9 |
7.6±23.5 |
5.4±15.0 |
11.2±23.6 |
−4.2±9.6 |
0.26 |
| 参数,µ摩尔/升 |
85.87±8.21 |
88.36±17.17 |
92.81±7.42 |
88.33±11.37 |
90.68±11.85 |
85.12±9.07 |
0.55 |
| ΔARG, % |
- - - - - - |
3.4±19.7 |
8.4±2.3 |
2.6±7.6 |
5.4±7.2 |
−0.8±7.5 |
0.52 |
| ADMA: nmol /参数µ摩尔 |
7.01±1.33 |
7.12±1.52 |
6.74±0.54 |
7.11±0.96 |
7.23±0.84 |
6.74±1.11 |
0.90 |
| ΔADMA:参数,% |
- - - - - - |
1.8±13.2 |
−0.8±21.6 |
3.0±14.7 |
5.6±18.2 |
−3.4±7.9 |
0.86 |
|
|
数据意味着±SD;。Δ,从之前的相对变化;ADMA dimethylarginine不对称;参数,精氨酸;MDA(丙二醛。从之前的;__
从职位。
|
